政策利好为国产创新药培育耐心资本

Group 1 - China's innovative drugs have gained a strong reputation globally, with significant clinical data replicability recognized by international pharmaceutical leaders [1] - In 2024, Chinese pharmaceutical companies completed over 90 overseas licensing transactions, totaling more than $50 billion, with $48 billion achieved in the first half of the year alone, indicating rapid growth [1] - The period from 2015 to the present is considered crucial for the development of China's innovative drugs, driven by supportive policies [2] Group 2 - The introduction of the "Support Measures for High-Quality Development of Innovative Drugs" is seen as a positive development for the industry, encouraging long-term investment in innovative drug research [2][3] - The establishment of a commercial health insurance directory for innovative drugs is expected to provide greater development opportunities for domestic innovative drug companies, shifting reliance from public insurance to a dual support system [3] - The National Medical Insurance Bureau reported a significant increase in spending on innovative drugs, with 2024 expenditures projected to be 3.9 times that of 2020, reflecting a 40% annual growth rate [4]